Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  2. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The collagen receptor uPARAP/Endo180 regulates collectins through unique structural elements in its FNII domain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

A key task in developing the field of personalized cancer therapy is the identification of novel molecular targets that enable treatment of cancers not susceptible to other means of specific therapy. The collagen receptor uPARAP/Endo180 is overexpressed by malignant cells in several non-epithelial cancers, notably including sarcomas, glioblastomas and subsets of acute myeloid leukemia. In contrast, in healthy adult individuals, expression is restricted to minor subsets of mesenchymal cells. Functionally, uPARAP/Endo180 is a rapidly recycling endocytic receptor that delivers its cargo directly into the endosomal-lysosomal system, thus opening a potential route of entry into receptor-positive cells. This combination of specific expression and endocytic function appears well suited for targeting of uPARAP/Endo180-positive cancers by antibody-drug conjugate (ADC) mediated drug delivery. Therefore, we utilized a specific monoclonal antibody against uPARAP/Endo180, raised through immunization of a uPARAP/Endo180 knock-out mouse, which reacts with both the human and the murine receptor, to construct a uPARAP-directed ADC. This antibody was coupled to the highly toxic dolastatin derivative, monomethyl auristatin E, via a cathepsin-labile valine-citrulline linker. With this ADC, we show strong and receptor-dependent cytotoxicity in vitro in uPARAP/Endo180-positive cancer cell lines of sarcoma, glioblastoma and leukemic origin. Furthermore, we demonstrate the potency of the ADC in vivo in a xenograft mouse model with human uPARAP/Endo180-positive leukemic cells, obtaining a complete cure of all tested mice following intravenous ADC treatment with no sign of adverse effects. Our study identifies uPARAP/Endo180 as a promising target for novel therapy against several highly malignant cancer types.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind8
Udgave nummer27
Sider (fra-til)44605-44624
Antal sider20
ISSN1949-2553
DOI
StatusUdgivet - 4 jul. 2017

ID: 52425427